Ipstyl Autogel (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, especially SSTR2 and SSTR5, on target cells. This binding inhibits adenylate cyclase, reduces cyclic AMP, and suppresses the secretion of growth hormone, insulin, glucagon, and other peptide hormones, thereby controlling disease activity.

The specific dose and dosing interval of Ipstyl Autogel are determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal hormonal control while minimizing adverse effects.

Safety data for lanreotide in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Ipstyl Autogel (lanreotide) and other long‑acting somatostatin analogues such as octreotide LAR share a similar mechanism of receptor binding and clinical indications. Differences lie in dosing frequency, formulation stability, and individual patient tolerability. Choice of therapy is guided by physician assessment of efficacy, convenience, and safety profile for each patient.

Ipstyl Autogel should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as this may affect product stability.

Ipstyl Autogel is given as a subcutaneous injection by a qualified healthcare professional. The formulation is a pre‑filled autoinjector or vial designed for deep subcutaneous delivery, typically administered in the abdomen, thigh or upper arm according to the prescriber’s instructions.

Serious risks include gallstone formation, acute pancreatitis, severe hyperglycemia that can lead to diabetic ketoacidosis, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of abdominal pain, jaundice, sudden changes in blood glucose, or any hypersensitivity symptoms.

Ipstyl Autogel is contraindicated in individuals with known hypersensitivity to lanreotide or any component of the formulation. Caution is advised for patients with uncontrolled diabetes, active gallbladder disease, severe hepatic or renal impairment, and pregnant or nursing women unless the benefit justifies the risk.